Dosing implications for liposomal amphotericin B in pregnancy
© 2023 Pharmacotherapy Publications, Inc..
Liposomal amphotericin B (LAmB) is used in the treatment of opportunistic fungal and parasitic infections, including leishmaniasis. Given its lack of known teratogenicity in pregnancy, LAmB is a preferred agent for treatment for these patients. However, significant gaps remain in determining optimal dosing regimens for LAmB in pregnancy. We describe the use of LAmB for a pregnant patient with mucocutaneous leishmaniasis (MCL) using a dosing strategy of 5 mg/kg/day for days 1-7 using ideal body weight followed by 4 mg/kg weekly using adjusted body weight. We reviewed the literature for LAmB dosing strategies, particularly dosing weight, in pregnancy. Of the 143 cases identified in 17 studies, only one reported a dosing weight, in which ideal body weight was used. Five Infectious Diseases Society of America guidelines in total discussed the use of amphotericin B in pregnancy but no guidelines included recommendations for dosing weight. This review describes our experience in using ideal body weight for dosing LAmB in pregnancy for the treatment of MCL. Use of ideal body weight may minimize risk of adverse effects to the fetus compared to the use of total body weight while maintaining efficacy for treatment of MCL in pregnancy.
| Errataetall: |
CommentIn: Pharmacotherapy. 2023 Sep;43(9):991. - PMID 37701937 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Pharmacotherapy - 43(2023), 5 vom: 01. Mai, Seite 452-462 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O'Grady, Niamh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7XU7A7DROE |
|---|
| Anmerkungen: |
Date Completed 17.05.2023 Date Revised 20.09.2023 published: Print-Electronic CommentIn: Pharmacotherapy. 2023 Sep;43(9):991. - PMID 37701937 Citation Status MEDLINE |
|---|
| doi: |
10.1002/phar.2784 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353679976 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353679976 | ||
| 003 | DE-627 | ||
| 005 | 20231226060549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/phar.2784 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353679976 | ||
| 035 | |a (NLM)36862037 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a O'Grady, Niamh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dosing implications for liposomal amphotericin B in pregnancy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2023 | ||
| 500 | |a Date Revised 20.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Pharmacotherapy. 2023 Sep;43(9):991. - PMID 37701937 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Pharmacotherapy Publications, Inc. | ||
| 520 | |a Liposomal amphotericin B (LAmB) is used in the treatment of opportunistic fungal and parasitic infections, including leishmaniasis. Given its lack of known teratogenicity in pregnancy, LAmB is a preferred agent for treatment for these patients. However, significant gaps remain in determining optimal dosing regimens for LAmB in pregnancy. We describe the use of LAmB for a pregnant patient with mucocutaneous leishmaniasis (MCL) using a dosing strategy of 5 mg/kg/day for days 1-7 using ideal body weight followed by 4 mg/kg weekly using adjusted body weight. We reviewed the literature for LAmB dosing strategies, particularly dosing weight, in pregnancy. Of the 143 cases identified in 17 studies, only one reported a dosing weight, in which ideal body weight was used. Five Infectious Diseases Society of America guidelines in total discussed the use of amphotericin B in pregnancy but no guidelines included recommendations for dosing weight. This review describes our experience in using ideal body weight for dosing LAmB in pregnancy for the treatment of MCL. Use of ideal body weight may minimize risk of adverse effects to the fetus compared to the use of total body weight while maintaining efficacy for treatment of MCL in pregnancy | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a ideal body weight | |
| 650 | 4 | |a leishmaniasis | |
| 650 | 4 | |a liposomal amphotericin B | |
| 650 | 4 | |a mucocutaneous | |
| 650 | 4 | |a pregnancy | |
| 650 | 7 | |a liposomal amphotericin B |2 NLM | |
| 650 | 7 | |a Amphotericin B |2 NLM | |
| 650 | 7 | |a 7XU7A7DROE |2 NLM | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a McManus, Dayna |e verfasserin |4 aut | |
| 700 | 1 | |a Briggs, Neima |e verfasserin |4 aut | |
| 700 | 1 | |a Azar, Marwan M |e verfasserin |4 aut | |
| 700 | 1 | |a Topal, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Matthew W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacotherapy |d 1983 |g 43(2023), 5 vom: 01. Mai, Seite 452-462 |w (DE-627)NLM012960926 |x 1875-9114 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:5 |g day:01 |g month:05 |g pages:452-462 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/phar.2784 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 5 |b 01 |c 05 |h 452-462 | ||